It allows for a further period during which more shares can be accumulated at these bargain prices?
Best I could do off the cuff...
May or may not turn out to be accurate.
TBH, if the data was crap and they had no hope of achieving an approval anywhere on the basis of this trial alone, then they really would have had an obligation to publically disclose as much.
Still reckon they are 'active' in the UK, in a fashion that has involved discussions with the MHRA.
Cash burn hopefully is now much-reduced, with the trial effectively over, and the CRO paid off (hopefully).
With the inputs into Sawston now being the main focus of effort and current expenditure.
I still find it wryly amusing that the strangely under-performing Optune control arm, with a meagre OS60 of 5% will be perhaps the main comparator for the DCVax-L treatment arm (OS60 estimated at 21%) in the data analysis, in UK and Europe at least.
Not an exact like for like in terms of trial subject criteria, but not far off.
I am looking for NICE to recommence their appraisal before too much longer. They need to get a data submission at the same time as the MHRA get an MAA for that to happen.
And for Sawston to gain their manufacturing licence.
Any development on these two issues would tell me that something is tracking to plan.
Yes, it's all a bit tedious right now. But c'est la vie...